Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Cash from Financing Activities (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Cash from Financing Activities for 9 consecutive years, with $192.1 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 4709.72% to $192.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $189.2 million through Dec 2025, down 60.93% year-over-year, with the annual reading at $189.2 million for FY2025, 60.93% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was $192.1 million at Denali Therapeutics, up from -$778000.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $500.3 million in Q1 2024, with the low at -$18.6 million in Q3 2024.
  • Average Cash from Financing Activities over 5 years is $51.1 million, with a median of $4.1 million recorded in 2021.
  • Peak annual rise in Cash from Financing Activities hit 31089.21% in 2024, while the deepest fall reached 844.74% in 2024.
  • Over 5 years, Cash from Financing Activities stood at $5.2 million in 2021, then skyrocketed by 5698.2% to $299.7 million in 2022, then plummeted by 98.43% to $4.7 million in 2023, then plummeted by 188.59% to -$4.2 million in 2024, then soared by 4709.72% to $192.1 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $192.1 million, -$778000.0, and $1.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.